Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30922836 | 1.00 | RXRA (0.35) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31691699 | 0.91 | RXRA (0.35) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL30922537 | 0.88 | CYP4F2 (0.37) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31527282 | 0.86 | RXRA (0.37) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31127821 | 0.86 | RXRA (0.37) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL24535801 | 0.86 | RXRA (0.37) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31127844 | 0.86 | RXRA (0.37) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31643015 | 0.86 | RXRA (0.37) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31127777 | 0.86 | RXRA (0.37) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31642882 | 0.86 | RXRA (0.37) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | RXRA 1531/4885RXRB 1041/4885RXRG 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.